Silvio Danese
Impact in
- Genetics top 0.01%
- Inflammatory Bowel Disease
- Gastroenterology top 0.05%
Papers in
- Genetics 876
- Inflammatory Bowel Disease 870
- Epidemiology 374
- Microscopic Colitis 322
- Autoimmune and Inflammatory Disorders 54
- Co-authors
- Laurent Peyrin‐Biroulet (251 shared papers)Claudio Fiocchi (24 shared papers)Gionata Fiorino (219 shared papers)William J. Sandborn (149 shared papers)Bruce E. Sands (129 shared papers)Ferdinando D’Amico (137 shared papers)Jean‐Frédéric Colombel (55 shared papers)Brian G. Feagan (95 shared papers)
- Journals
- Journal of Crohn s and Colitis (278 papers)Gastroenterology (157 papers)The American Journal of Gastroenterology (68 papers)Alimentary Pharmacology & Therapeutics (49 papers)Digestive and Liver Disease (45 papers)
- Partner nations
- ItalyFranceUnited States
In The Last Decade
Silvio Danese
1.2k papers receiving 51.3k citations
Silvio Danese's Hit Papers
Peers
Comparison fields: 5 of 180
- Genetics 27.5k
- Gastroenterology 2.4k
- Immunology 9.4k
- Epidemiology 11.4k
- Hematology 2.7k
Countries citing papers authored by Silvio Danese
This map shows the geographic impact of Silvio Danese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvio Danese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvio Danese more than expected).
Fields of papers citing papers by Silvio Danese
This network shows the impact of papers produced by Silvio Danese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvio Danese. The network helps show where Silvio Danese may publish in the future.
Co-authors
The 25 scholars most cited alongside Silvio Danese, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2013 | 2090 |
| 2 | STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD Hit paper breakdown → | 2021 | 1627 |
| 3 | Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2017 | 1257 |
| 4 | Ulcerative colitis Hit paper breakdown → | 2020 | 1151 |
| 5 | The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management Hit paper breakdown → | 2010 | 1139 |
| 6 | Ulcerative Colitis Hit paper breakdown → | 2011 | 900 |
| 7 | Epithelial NEMO links innate immunity to chronic intestinal inflammation Hit paper breakdown → | 2007 | 879 |
| 8 | Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2019 | 819 |
| 9 | Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial Hit paper breakdown → | 2016 | 755 |
| 10 | Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis Hit paper breakdown → | 2013 | 696 |
| 11 | Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Hit paper breakdown → | 2011 | 672 |
| 12 | Crohn’s disease Hit paper breakdown → | 2020 | 671 |
| 13 | The safety of vedolizumab for ulcerative colitis and Crohn's disease Hit paper breakdown → | 2016 | 575 |
| 14 | Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Hit paper breakdown → | 2019 | 530 |
| 15 | 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations Hit paper breakdown → | 2016 | 518 |
| 16 | Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Hit paper breakdown → | 2019 | 482 |
| 17 | European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases Hit paper breakdown → | 2014 | 432 |
| 18 | 2020 | 403 | |
| 19 | 2006 | 395 | |
| 20 | Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis Hit paper breakdown → | 2021 | 351 |
About Silvio Danese
Silvio Danese is a scholar working on Genetics, Epidemiology, Surgery, Immunology and Oncology, having authored 1.3k papers that have together received 52.2k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (870 papers), Microscopic Colitis (322 papers), Eosinophilic Esophagitis (101 papers), Biosimilars and Bioanalytical Methods (93 papers), Helicobacter pylori-related gastroenterology studies (78 papers), Immunodeficiency and Autoimmune Disorders (60 papers), Autoimmune and Inflammatory Disorders (54 papers) and Liver Diseases and Immunity (46 papers). The work is most often cited by research in Genetics (27.5k citations), Gastroenterology (2.4k citations), Immunology (9.4k citations), Epidemiology (11.4k citations) and Hematology (2.7k citations). Silvio Danese has collaborated with scholars based in Italy, France and United States. Frequent co-authors include Laurent Peyrin‐Biroulet, Claudio Fiocchi, Gionata Fiorino, William J. Sandborn, Bruce E. Sands, Ferdinando D’Amico, Jean‐Frédéric Colombel, Brian G. Feagan, Stefanos Bonovas and Remo Panaccione. Their work appears in journals such as Journal of Crohn s and Colitis, Gastroenterology, The American Journal of Gastroenterology, Alimentary Pharmacology & Therapeutics and Digestive and Liver Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.